Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation

  1. Ceri Alan Fielding
  2. Michael P Weekes
  3. Luis V Nobre
  4. Eva Ruckova
  5. Gavin S Wilkie
  6. Joao A Paulo
  7. Chiwen Chang
  8. Nicolás M Suárez
  9. James A Davies
  10. Robin Antrobus
  11. Richard J Stanton
  12. Rebecca J Aicheler
  13. Hester Nichols
  14. Borek Vojtesek
  15. John Trowsdale
  16. Andrew J Davison
  17. Steven P Gygi
  18. Peter Tomasec
  19. Paul J Lehner
  20. Gavin WG Wilkinson  Is a corresponding author
  1. Cardiff University School of Medicine, United Kingdom
  2. Cambridge Institute for Medical Research, United Kingdom
  3. Masaryk Memorial Cancer Institute, Czech Republic
  4. MRC-University of Glasgow Centre for Virus Research, United Kingdom
  5. Harvard Medical School, United States
  6. University of Cambridge, United Kingdom
  7. Cardiff Metropolitan University, United Kingdom

Abstract

The human cytomegalovirus (HCMV) US12 family consists of ten sequentially arranged genes (US12-21) with poorly characterized function. We now identify novel NK cell evasion functions for four members: US12, US14, US18 and US20. Using a systematic multiplexed proteomics approach to quantify ~1,300 cell surface and ~7,200 whole cell proteins, we demonstrate that the US12 family selectively targets plasma membrane proteins and plays key roles in regulating NK ligands, adhesion molecules and cytokine receptors. US18 and US20 work in concert to suppress cell surface expression of the critical NKp30 ligand B7-H6 thus inhibiting NK cell activation. The US12 family is therefore identified as a major new hub of immune regulation.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Ceri Alan Fielding

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5817-3153
  2. Michael P Weekes

    Cambridge Institute for Medical Research, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Luis V Nobre

    Cambridge Institute for Medical Research, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Eva Ruckova

    Regional Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  5. Gavin S Wilkie

    MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Joao A Paulo

    Department of Cell Biology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Chiwen Chang

    Immunology Division, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Nicolás M Suárez

    MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. James A Davies

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Robin Antrobus

    Cambridge Institute for Medical Research, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Richard J Stanton

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Rebecca J Aicheler

    Cardiff School of Health Sciences, Cardiff Metropolitan University, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Hester Nichols

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Borek Vojtesek

    Regional Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  15. John Trowsdale

    Immunology Division, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Andrew J Davison

    MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Steven P Gygi

    Department of Cell Biology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Peter Tomasec

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Paul J Lehner

    Cambridge Institute for Medical Research, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9383-1054
  20. Gavin WG Wilkinson

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
    For correspondence
    Wilkinsongw1@cardiff.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5623-0126

Funding

Medical Research Council (MRC G1000236,MR/L018373/1)

  • Peter Tomasec
  • Gavin WG Wilkinson

European Research Council (695551)

  • John Trowsdale

Wellcome (WT090323MA)

  • Peter Tomasec
  • Gavin WG Wilkinson

Wellcome (WT101835)

  • Paul J Lehner

Wellcome (108070/Z/15/Z)

  • Michael P Weekes

NIH/NIDDK (K01 DK098285)

  • Joao A Paulo

Czech Science Foundation (P206/12/G151)

  • Borek Vojtesek

Medical Research Council (G0901682)

  • John Trowsdale

European Research Council (695551)

  • John Trowsdale

Wellcome (100140)

  • Paul J Lehner

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Healthy adult volunteers provided blood for this study following written informed consent (approved by the Cardiff University School of Medicine Ethics Committee Ref. no: 10/20) or buffy coats provided by the Welsh Blood Service, following informed consent.

Copyright

© 2017, Fielding et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,868
    views
  • 627
    downloads
  • 61
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ceri Alan Fielding
  2. Michael P Weekes
  3. Luis V Nobre
  4. Eva Ruckova
  5. Gavin S Wilkie
  6. Joao A Paulo
  7. Chiwen Chang
  8. Nicolás M Suárez
  9. James A Davies
  10. Robin Antrobus
  11. Richard J Stanton
  12. Rebecca J Aicheler
  13. Hester Nichols
  14. Borek Vojtesek
  15. John Trowsdale
  16. Andrew J Davison
  17. Steven P Gygi
  18. Peter Tomasec
  19. Paul J Lehner
  20. Gavin WG Wilkinson
(2017)
Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation
eLife 6:e22206.
https://doi.org/10.7554/eLife.22206

Share this article

https://doi.org/10.7554/eLife.22206

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Armando Montoya-Garcia, Idaira M Guerrero-Fonseca ... Michael Schnoor
    Research Article

    Arpin was discovered as an inhibitor of the Arp2/3 complex localized at the lamellipodial tip of fibroblasts, where it regulated migration steering. Recently, we showed that arpin stabilizes the epithelial barrier in an Arp2/3-dependent manner. However, the expression and functions of arpin in endothelial cells (EC) have not yet been described. Arpin mRNA and protein are expressed in EC and downregulated by pro-inflammatory cytokines. Arpin depletion in Human Umbilical Vein Endothelial Cells causes the formation of actomyosin stress fibers leading to increased permeability in an Arp2/3-independent manner. Instead, inhibitors of ROCK1 and ZIPK, kinases involved in the generation of stress fibers, normalize the loss-of-arpin effects on actin filaments and permeability. Arpin-deficient mice are viable but show a characteristic vascular phenotype in the lung including edema, microhemorrhage, and vascular congestion, increased F-actin levels, and vascular permeability. Our data show that, apart from being an Arp2/3 inhibitor, arpin is also a regulator of actomyosin contractility and endothelial barrier integrity.

    1. Immunology and Inflammation
    Alexandra a Aybar-Torres, Lennon A Saldarriaga ... Lei Jin
    Research Article

    The significance of STING1 gene in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human STING1 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ~60% of East Asians and ~40% of Africans, respectively. Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human STING1 mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using Sting1 knock-in mice expressing common human STING1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING1-mediated cell death ex vivo, establishing a critical role of STING1 residue 293 in cell death. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4 T cellpenia. The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (~10-fold, ~20-fold, respectively) T-regs than WT/SAVI(N153S) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the WT/SAVI, the AQ/SAVI mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING1 activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant HAQ, AQ alleles. STING1 research and STING1-targeting immunotherapy should consider STING1 heterogeneity in humans.